Ownership Filing for Terrie Kellmeyer

This filing details the ownership of Anavex Life Sciences Corp. (AVXL) by Terrie Kellmeyer, Interim CEO. The filing reports on options to purchase common stock, including vested and unvested options. Specifically, it lists 35,001 vested and 11,667 unvested options with an exercise price of $7.21, set to vest in two tranches by September 30, 2026. Additionally, 2,500 vested and 5,000 unvested options with an exercise price of $5.36 are reported, with vesting tied to performance milestones. Finally, 25,000 vested and 25,000 unvested options with an exercise price of $8.58 are disclosed, also subject to performance-based vesting. The reporting date for this information is May 4, 2026.